Peak incidence of rotavirus gastroenteritis is seen in infants between 6 and 24 months of age. The researchers therefore aimed to assess the 2-year efficacy and safety of an oral live attenuated human rotavirus vaccine for prevention of severe gastroenteritis in infants.